HRSA Psychedelic Therapy RFI: What It Means for Patients

HRSA Asked How to Train and Deliver Psychedelic Therapy, Stakeholders Answered

The Health Resources and Services Administration (HRSA), a Department of Health and Human Services (HHS) agency best known for funding community health centers and the National Health Service Corps, has received 59 public comments in response to a request for information (RFI) it issued on training and care delivery models for administering psychedelic therapies in outpatient, or 'ambulatory,' settings, according to reporting from Psychedelic Alpha published August 20, 2026. A request for information is a formal mechanism federal agencies use to gather public and industry input before drafting guidance or rules, it does not itself create new regulations, but it signals that an agency is actively shaping policy on a topic.

Per Psychedelic Alpha's reporting, the RFI centers on how clinicians would be credentialed and how clinics would be structured and staffed if the FDA approves additional psychedelic-assisted therapies, such as psilocybin or MDMA-assisted treatments, which remain under agency review rather than approved. The article's title frames the comments as clustering around three themes: credentials, clinics, and costs, pointing to workforce training standards, care-delivery models, and the financial structure of future treatment programs as the areas stakeholders most wanted to weigh in on. Psychedelic Alpha has not published the full text or a breakdown of the 59 comments in the material provided here, so specific positions taken by individual commenters are not yet confirmed beyond this framing.

Ketamine Is Already Approved, This RFI Is About What Comes Next

It's worth being precise about where ketamine fits into this story. Ketamine itself has been FDA-approved as an anesthetic for decades, and esketamine (brand name Spravato) has been FDA-approved since 2019 specifically for treatment-resistant depression when combined with an oral antidepressant. Off-label IV and sublingual ketamine for depression, anxiety, and other conditions operates under a different, less formally standardized regulatory posture. HRSA's RFI, by contrast, is aimed at psychedelics that are not yet FDA-approved, most notably psilocybin and MDMA, and is forward-looking: it's asking how the healthcare system should train providers and structure clinics if and when those substances clear FDA review.

What This Means For Ketamine Clinic Patients

Even though this RFI doesn't directly regulate ketamine, it's a useful signal for readers evaluating ketamine telehealth and in-person providers today, because the exact issues HRSA is soliciting comments on, credentialing, care-delivery models, and cost transparency, are the same questions that separate reputable ketamine clinics from lower-quality ones in the current, less standardized market. A few practical takeaways:

• Ask about provider credentials directly. Confirm who is prescribing (a licensed physician, nurse practitioner, or psychiatrist), who is supervising dosing sessions, and whether that person has specific training in ketamine-assisted treatment rather than general telehealth prescribing.
• Understand the care-delivery model before you start. Reputable programs typically include an intake screening for medical and psychiatric history, a defined dosing and monitoring protocol, and structured follow-up care, not just a one-time prescription. If a provider can't clearly describe this model, that's a warning sign.
• Get cost expectations in writing up front. Because ketamine for depression and anxiety is largely used off-label, insurance coverage is inconsistent, and pricing varies widely between telehealth platforms and in-person clinics. Ask for a full breakdown of intake, dosing session, and follow-up costs before committing.
• Watch for future regulatory movement. If HRSA moves from this RFI toward formal guidance on psychedelic therapy training and delivery, that framework could eventually influence how ketamine clinics, many of which already operate adjacent to this emerging psychedelic-medicine field, are expected to structure credentialing and care standards, even though ketamine itself sits outside the immediate scope of this particular request.

For now, this remains a policy-development story to watch rather than a change that affects current ketamine access, state availability, or out-of-pocket costs. Readers considering treatment should continue to vet providers using the same credentialing, safety-screening, and follow-up-care criteria this site has consistently recommended, and can review HRSA's original RFI activity and the full list of stakeholder comments through Psychedelic Alpha's reporting as it develops.